Cargando…

Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study

AIMS : We aimed to provide contemporary real-world data on wearable cardioverter-defibrillator (WCD) use, not only in terms of effectiveness and safety but also compliance and acceptability. METHODS AND RESULTS : Across 88 French centres, the WEARIT-France study enrolled retrospectively patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia, Rodrigue, Combes, Nicolas, Defaye, Pascal, Narayanan, Kumar, Guedon-Moreau, Laurence, Boveda, Serge, Blangy, Hugues, Bouet, Jérôme, Briand, Florent, Chevalier, Philippe, Cottin, Yves, Da Costa, Antoine, Degand, Bruno, Deharo, Jean-Claude, Eschalier, Romain, Extramiana, Fabrice, Goralski, Marc, Guy-Moyat, Benoit, Guyomar, Yves, Hermida, Jean-Sylvain, Jourda, François, Lellouche, Nicolas, Mahfoud, Mohanad, Manenti, Vladimir, Mansourati, Jacques, Martin, Angéline, Pasquié, Jean-Luc, Ritter, Philippe, Rollin, Anne, Tibi, Thierry, Yalioua, Arab, Gras, Daniel, Sadoul, Nicolas, Piot, Olivier, Leclercq, Christophe, Marijon, Eloi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842091/
https://www.ncbi.nlm.nih.gov/pubmed/33257972
http://dx.doi.org/10.1093/europace/euaa268
_version_ 1783643943765803008
author Garcia, Rodrigue
Combes, Nicolas
Defaye, Pascal
Narayanan, Kumar
Guedon-Moreau, Laurence
Boveda, Serge
Blangy, Hugues
Bouet, Jérôme
Briand, Florent
Chevalier, Philippe
Cottin, Yves
Da Costa, Antoine
Degand, Bruno
Deharo, Jean-Claude
Eschalier, Romain
Extramiana, Fabrice
Goralski, Marc
Guy-Moyat, Benoit
Guyomar, Yves
Hermida, Jean-Sylvain
Jourda, François
Lellouche, Nicolas
Mahfoud, Mohanad
Manenti, Vladimir
Mansourati, Jacques
Martin, Angéline
Pasquié, Jean-Luc
Ritter, Philippe
Rollin, Anne
Tibi, Thierry
Yalioua, Arab
Gras, Daniel
Sadoul, Nicolas
Piot, Olivier
Leclercq, Christophe
Marijon, Eloi
author_facet Garcia, Rodrigue
Combes, Nicolas
Defaye, Pascal
Narayanan, Kumar
Guedon-Moreau, Laurence
Boveda, Serge
Blangy, Hugues
Bouet, Jérôme
Briand, Florent
Chevalier, Philippe
Cottin, Yves
Da Costa, Antoine
Degand, Bruno
Deharo, Jean-Claude
Eschalier, Romain
Extramiana, Fabrice
Goralski, Marc
Guy-Moyat, Benoit
Guyomar, Yves
Hermida, Jean-Sylvain
Jourda, François
Lellouche, Nicolas
Mahfoud, Mohanad
Manenti, Vladimir
Mansourati, Jacques
Martin, Angéline
Pasquié, Jean-Luc
Ritter, Philippe
Rollin, Anne
Tibi, Thierry
Yalioua, Arab
Gras, Daniel
Sadoul, Nicolas
Piot, Olivier
Leclercq, Christophe
Marijon, Eloi
author_sort Garcia, Rodrigue
collection PubMed
description AIMS : We aimed to provide contemporary real-world data on wearable cardioverter-defibrillator (WCD) use, not only in terms of effectiveness and safety but also compliance and acceptability. METHODS AND RESULTS : Across 88 French centres, the WEARIT-France study enrolled retrospectively patients who used the WCD between May 2014 and December 2016, and prospectively all patients equipped for WCD therapy between January 2017 and March 2018. All patients received systematic education session through a standardized programme across France at the time of initiation of WCD therapy and were systematically enrolled in the LifeVest Network remote services. Overall, 1157 patients were included (mean age 60 ± 12 years, 16% women; 46% prospectively): 82.1% with ischaemic cardiomyopathy, 10.3% after implantable cardioverter-defibrillator explant, and 7.6% before heart transplantation. Median WCD usage period was 62 (37–97) days. Median daily wear time of WCD was 23.4 (22.2–23.8) h. In multivariate analysis, younger age was associated with lower compliance [adjusted odds ratio (OR) 0.97, 95% confidence interval (CI) 0.95–0.99, P < 0.01]. A total of 18 participants (1.6%) received at least one appropriate shock, giving an incidence of appropriate therapy of 7.2 per 100 patient-years. Patient-response button allowed the shock to be aborted in 35.7% of well-tolerated sustained ventricular arrhythmias and in 95.4% of inappropriate ventricular arrhythmia detection, finally resulting in an inappropriate therapy in eight patients (0.7%). CONCLUSION: Our real-life findings reinforce previous studies on the efficacy and safety of the WCD in the setting of transient high-risk group in selected patients. Moreover, they emphasize the fact that when prescribed appropriately, in concert with adequate patient education and dedicated follow-up using specific remote monitoring system, compliance with WCD is high and the device well-tolerated by the patient.
format Online
Article
Text
id pubmed-7842091
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-78420912021-02-02 Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study Garcia, Rodrigue Combes, Nicolas Defaye, Pascal Narayanan, Kumar Guedon-Moreau, Laurence Boveda, Serge Blangy, Hugues Bouet, Jérôme Briand, Florent Chevalier, Philippe Cottin, Yves Da Costa, Antoine Degand, Bruno Deharo, Jean-Claude Eschalier, Romain Extramiana, Fabrice Goralski, Marc Guy-Moyat, Benoit Guyomar, Yves Hermida, Jean-Sylvain Jourda, François Lellouche, Nicolas Mahfoud, Mohanad Manenti, Vladimir Mansourati, Jacques Martin, Angéline Pasquié, Jean-Luc Ritter, Philippe Rollin, Anne Tibi, Thierry Yalioua, Arab Gras, Daniel Sadoul, Nicolas Piot, Olivier Leclercq, Christophe Marijon, Eloi Europace Clinical Research AIMS : We aimed to provide contemporary real-world data on wearable cardioverter-defibrillator (WCD) use, not only in terms of effectiveness and safety but also compliance and acceptability. METHODS AND RESULTS : Across 88 French centres, the WEARIT-France study enrolled retrospectively patients who used the WCD between May 2014 and December 2016, and prospectively all patients equipped for WCD therapy between January 2017 and March 2018. All patients received systematic education session through a standardized programme across France at the time of initiation of WCD therapy and were systematically enrolled in the LifeVest Network remote services. Overall, 1157 patients were included (mean age 60 ± 12 years, 16% women; 46% prospectively): 82.1% with ischaemic cardiomyopathy, 10.3% after implantable cardioverter-defibrillator explant, and 7.6% before heart transplantation. Median WCD usage period was 62 (37–97) days. Median daily wear time of WCD was 23.4 (22.2–23.8) h. In multivariate analysis, younger age was associated with lower compliance [adjusted odds ratio (OR) 0.97, 95% confidence interval (CI) 0.95–0.99, P < 0.01]. A total of 18 participants (1.6%) received at least one appropriate shock, giving an incidence of appropriate therapy of 7.2 per 100 patient-years. Patient-response button allowed the shock to be aborted in 35.7% of well-tolerated sustained ventricular arrhythmias and in 95.4% of inappropriate ventricular arrhythmia detection, finally resulting in an inappropriate therapy in eight patients (0.7%). CONCLUSION: Our real-life findings reinforce previous studies on the efficacy and safety of the WCD in the setting of transient high-risk group in selected patients. Moreover, they emphasize the fact that when prescribed appropriately, in concert with adequate patient education and dedicated follow-up using specific remote monitoring system, compliance with WCD is high and the device well-tolerated by the patient. Oxford University Press 2020-11-30 /pmc/articles/PMC7842091/ /pubmed/33257972 http://dx.doi.org/10.1093/europace/euaa268 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Research
Garcia, Rodrigue
Combes, Nicolas
Defaye, Pascal
Narayanan, Kumar
Guedon-Moreau, Laurence
Boveda, Serge
Blangy, Hugues
Bouet, Jérôme
Briand, Florent
Chevalier, Philippe
Cottin, Yves
Da Costa, Antoine
Degand, Bruno
Deharo, Jean-Claude
Eschalier, Romain
Extramiana, Fabrice
Goralski, Marc
Guy-Moyat, Benoit
Guyomar, Yves
Hermida, Jean-Sylvain
Jourda, François
Lellouche, Nicolas
Mahfoud, Mohanad
Manenti, Vladimir
Mansourati, Jacques
Martin, Angéline
Pasquié, Jean-Luc
Ritter, Philippe
Rollin, Anne
Tibi, Thierry
Yalioua, Arab
Gras, Daniel
Sadoul, Nicolas
Piot, Olivier
Leclercq, Christophe
Marijon, Eloi
Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study
title Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study
title_full Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study
title_fullStr Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study
title_full_unstemmed Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study
title_short Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study
title_sort wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the wearit-france cohort study
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842091/
https://www.ncbi.nlm.nih.gov/pubmed/33257972
http://dx.doi.org/10.1093/europace/euaa268
work_keys_str_mv AT garciarodrigue wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT combesnicolas wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT defayepascal wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT narayanankumar wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT guedonmoreaulaurence wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT bovedaserge wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT blangyhugues wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT bouetjerome wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT briandflorent wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT chevalierphilippe wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT cottinyves wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT dacostaantoine wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT degandbruno wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT deharojeanclaude wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT eschalierromain wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT extramianafabrice wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT goralskimarc wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT guymoyatbenoit wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT guyomaryves wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT hermidajeansylvain wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT jourdafrancois wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT lellouchenicolas wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT mahfoudmohanad wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT manentivladimir wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT mansouratijacques wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT martinangeline wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT pasquiejeanluc wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT ritterphilippe wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT rollinanne wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT tibithierry wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT yaliouaarab wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT grasdaniel wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT sadoulnicolas wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT piotolivier wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT leclercqchristophe wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy
AT marijoneloi wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy